Mar 04, 2024 8:00 am EST CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
Feb 28, 2024 4:45 pm EST CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
Feb 21, 2024 5:43 pm EST The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
Feb 12, 2024 8:45 am EST CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
Feb 12, 2024 8:30 am EST Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Jan 03, 2024 8:00 am EST New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
Jan 02, 2024 8:00 am EST CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024